Nitric oxide by NOxy Health Products for Diabetic Foot Ulcers: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Nitric oxide overview

Nitric oxide (NOX-1416) is under development for the treatment of diabetic foot ulcers. The drug candidate is administered through topical route in the form of foam. It acts by targeting guanylate cyclase.

NOxy Health Products overview

NOxy Health Products is a healthcare company that focuses on developing innovative medicines to heal chronic wounds with the help of nitric oxide. The company is headquartered in San Mateo, California, the US.

For a complete picture of Nitric oxide’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.